English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Mycoplasma bovis is pathogen known to cause respiratory disease, otitis   media, arthritis and a variety of additional diseases in cattle. Infections   caused by this pathogen have significant impact on the health, welfare and   productivity of dairy and beef cattle resulting in substantial economic   losses. Current preventive and treatment strategies rely on the use of   antimicrobials and vaccines; however, their efficacy is limited due to   difficult diagnosis and inconsistent disease expression. Here, we report   results on the use of Mycobacterium cell wall fraction (MCWF), an   immunomodulator, in dairy cows persistently infected with M. bovis during the   period 2011-2015. Application of MCWF aided in reducing M. bovis-associated   clinical signs, such as pneumonia, arthritis and mastitis, and improving   overall reproductive performance and days in lactation of infected dairy   cows. These results were compared to historical information on the health   status and farm performance for period 2011-2015, and suggest that MCWF   immunomodulator could be introduced as an aid in treatment protocols for   persistent infections with M. bovis in dairy cows

Immunomodulator, Mycobacterium cell wall fraction, an aid in control of persistent Mycoplasma bovis infection in dairy cows